Genmab AS (MEX:GMABN) Asset Turnover: 0.07 (As of Mar. 2026)


MEX:GMABN Genmab AS MEX:GMABN
92 GF Score
Price MXN4,027.79
GF Value MXN5,328.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Asset Turnover?

Genmab AS MEX:GMABN 92 Asset Turnover is 0.07 as of Mar. 2026. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Genmab AS's Revenue for the three months ended in Mar. 2026 was MXN16,157 Mil. Genmab AS's Total Assets for the quarter that ended in Mar. 2026 was MXN227,480 Mil. Therefore, Genmab AS's Asset Turnover for the quarter that ended in Mar. 2026 was 0.07.

Asset Turnover is linked to ROE % through Du Pont Formula. Genmab AS's annualized ROE % for the quarter that ended in Mar. 2026 was 3.68%. It is also linked to ROA % through Du Pont Formula. Genmab AS's annualized ROA % for the quarter that ended in Mar. 2026 was 1.68%.


Genmab AS  (MEX:GMABN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Genmab AS's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=3822.932/103870.5645
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(3822.932 / 64629.196)*(64629.196 / 227480.0355)*(227480.0355/ 103870.5645)
=Net Margin %*Asset Turnover*Equity Multiplier
=5.92 %*0.2841*2.19
=ROA %*Equity Multiplier
=1.68 %*2.19
=3.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Genmab AS's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=3822.932/227480.0355
=(Net Income / Revenue)*(Revenue / Total Assets)
=(3822.932 / 64629.196)*(64629.196 / 227480.0355)
=Net Margin %*Asset Turnover
=5.92 %*0.2841
=1.68 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Genmab AS Asset Turnover Related Terms


Genmab AS Asset Turnover Historical Data

* Premium members only.

The historical data trend for Genmab AS's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Asset Turnover Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.50 0.47 0.59 0.37

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.14 0.15 0.11 0.07

MEX:GMABN vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, Genmab AS's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Genmab AS's Asset Turnover falls into.


MEX:GMABN
92GF Score
Genmab AS MEX:GMABN
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Genmab AS's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=66981.204/( (133768.46+231787.376)/ 2 )
=66981.204/182777.918
=0.37

Genmab AS's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=16157.299/( (231787.376+223172.695)/ 2 )
=16157.299/227480.0355
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.07 mean?
Genmab AS (MEX:GMABN) has a Asset Turnover of 0.07 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Genmab AS and its competitors.
Is Genmab AS's Asset Turnover too high?
Genmab AS's current Asset Turnover is 0.07. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Asset Turnover compare to VRTX and REGN?
Genmab AS's Asset Turnover of 0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Genmab AS and its competitors. Genmab AS's current Asset Turnover is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Asset Turnover is 0.07. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Asset Turnover is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (MEX:GMABN) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for MEX:GMABN:

  • Asset Turnover: 0.07
  • GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score

Get the complete analysis for MEX:GMABN

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,027.79
Price
MXN5,328.99
GF Value